JW Life Science Corp
KRX:234080
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (3.5), the stock would be worth ₩16 510.85 (26% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.8 | ₩13 100 |
0%
|
| 3-Year Average | 3.5 | ₩16 510.85 |
+26%
|
| 5-Year Average | 4 | ₩18 522.84 |
+41%
|
| Industry Average | 3.8 | ₩17 854.71 |
+36%
|
| Country Average | 5.4 | ₩25 315.42 |
+93%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
JW Life Science Corp
KRX:234080
|
202.8B KRW | 2.8 | 7.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 16.9 | 42.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 8.8 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 6.4 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 5.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.4 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 5.2 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 4.2 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 4.4 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.7 |
| Median | 5.4 |
| 70th Percentile | 10.1 |
| Max | 19 609.2 |
Other Multiples
JW Life Science Corp
Glance View
JW Life Science Corp. manufactures intravenous fluids. The company is headquartered in Dangjin, Chungcheongnam-Do. The company went IPO on 2016-10-27. The firm is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The firm is also engaged in manufacture of total parenteral nutrition (TPN) products and others.
